Study guide
3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia
AMCB Certified Nurse-Midwife CNM
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Early Pregnancy — Diagnosis, History, Dating & Models of Care
1.1 Signs of Pregnancy, hCG Kinetics & Acceptance of Pregnancy 1.2 Prenatal History, Obstetric Notation & Gestational Dating 1.3 The Initial Prenatal Laboratory Panel 1.4 Prenatal Genetic Screening, Diagnostic Testing & Hereditary Risk 1.5 Models of Prenatal Care, Birth-Setting Counseling & Community Referral
2 Chapter 2: Ongoing Prenatal Assessment, Nutrition & Common Discomforts
2.1 Prenatal Visit Cadence, Milestone Screening & Fundal Height 2.2 Leopold Maneuvers, Fetal Heart Auscultation & Antepartum Surveillance 2.3 Clinical Pelvimetry & Assessment of the Bony Pelvis 2.4 Maternal Nutrition, Weight Gain & Immunization in Pregnancy 2.5 Nausea, Vomiting & Gastrointestinal Discomforts of Pregnancy 2.6 Musculoskeletal, Vascular & Neurologic Discomforts of Pregnancy
3 Chapter 3: Hypertensive, Endocrine & Hematologic Complications of Pregnancy
3.1 Classification & Diagnosis of Hypertensive Disorders of Pregnancy 3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia 3.3 Delivery Timing, Aspirin Prophylaxis & Postpartum Hypertension 3.4 Gestational Diabetes: Pathophysiology, Screening & Diagnosis 3.5 Glycemic Management, Fetal Surveillance & Delivery Timing in Gestational Diabetes 3.6 Thyroid Disorders & Anemia in Pregnancy
4 Chapter 4: Bleeding, Amniotic Fluid Disorders, Preterm Birth & Perinatal Loss
4.1 First-Trimester Bleeding, Early Pregnancy Loss & Gestational Trophoblastic Disease 4.2 Ectopic Pregnancy: Diagnosis & Management 4.3 Third-Trimester Bleeding & Amniotic Fluid Volume Disorders 4.4 Preterm Labor & Preterm Prelabor Rupture of Membranes 4.5 Intrauterine Fetal Demise, Stillbirth & Bereavement Care
5 Chapter 5: Normal Labor, Birth & Intrapartum Fetal Surveillance
5.1 Onset of Labor, True Versus False Labor & Nutrition in Labor 5.2 The First and Second Stages of Labor 5.3 Cardinal Movements, Third & Fourth Stages of Labor 5.4 Cord Clamping, Cord Blood, Cord Gases & Placental Examination 5.5 Fetal Oxygenation, Intermittent Auscultation & Uterine Activity Monitoring 5.6 Electronic Fetal Monitoring Parameters & the NICHD Categories 5.7 Intrauterine Resuscitation, Scalp Electrode & Amnioinfusion
6 Chapter 6: Labor Support, Analgesia, Induction & Augmentation
6.1 The Midwifery Model, Continuous Labor Support & Non-Pharmacologic Comfort 6.2 Water Immersion, Waterbirth & Non-Supine Birth Positions 6.3 Systemic, Neuraxial & Regional Analgesia in Labor 6.4 Indications & Timing for Induction of Labor 6.5 The Bishop Score & Cervical Ripening Methods 6.6 Oxytocin Titration, Tachysystole Management & Amniotomy
7 Chapter 7: Intrapartum Emergencies, Malpresentation & Perineal Repair
7.1 Shoulder Dystocia: Recognition & the HELPERR Protocol 7.2 Dystocia Complications, Umbilical Cord Prolapse & Intraamniotic Infection 7.3 Malposition, Manual Rotation, Breech, Face Presentation & Nuchal Cord 7.4 Perineal Anatomy & Classification of Obstetric Lacerations 7.5 Episiotomy & Surgical Perineal Repair 7.6 TOLAC, VBAC & Uterine Rupture
8 Chapter 8: The Normal Puerperium, Postpartum Assessment & Lactation
8.1 Puerperal Physiology, Uterine Involution & Lochia 8.2 The BUBBLE-HE Postpartum Assessment 8.3 Bladder, Bowel & Perineal Care and the Postpartum Care Continuum 8.4 Lactation Neuroendocrinology & the Stages of Lactogenesis 8.5 LATCH Assessment, Latch Biomechanics & Adequate Intake 8.6 Lactation Complications, Medication Safety & Contraindications
9 Chapter 9: Postpartum Contraception, Family Planning & Hemorrhage
9.1 Return of Fertility, Lactational Amenorrhea & US MEC in the Puerperium 9.2 Postpartum Hormonal Contraception & Intrauterine Devices 9.3 Barrier & Permanent Contraception, Postpartum Sexuality & Family Support 9.4 Postpartum Hemorrhage: Definition, Shock Recognition & Quantitative Blood Loss 9.5 The Four Ts: Etiology of Postpartum Hemorrhage 9.6 Hemorrhage Resuscitation, Uterotonics, TXA & Surgical Escalation
10 Chapter 10: Puerperal Infection, Thromboembolism, Cesarean Recovery & Perinatal Mental Health
10.1 Puerperal Endometritis & Septic Pelvic Thrombophlebitis 10.2 Puerperal Wound Infection, Mastitis & Breast Abscess 10.3 Postpartum Venous Thromboembolism 10.4 Post-Cesarean Recovery: Inpatient Care & Care After Discharge 10.5 Postpartum Blues, Depression & EPDS Screening 10.6 Treating Postpartum Depression, Anxiety, OCD & Psychosis
11 Chapter 11: Neonatal Transition, Resuscitation & the Newborn Examination
11.1 Fetal-to-Neonatal Transition & Circulatory Remodeling 11.2 APGAR Scoring & the NRP Initial Steps 11.3 Positive Pressure Ventilation, MR. SOPA & Advanced Resuscitation 11.4 Newborn Vital Signs, Anthropometrics & the Ballard Score 11.5 Cranial Assessment & Head-to-Chest Examination 11.6 Genitourinary & Musculoskeletal Examination and Primitive Reflexes
12 Chapter 12: Newborn Prophylaxis, Screening, Common Disorders & Care Through 28 Days
12.1 Standard Neonatal Prophylaxis: Vitamin K, Eye Ointment & Hepatitis B 12.2 Universal Newborn Screening: Hearing, CCHD & Dried Blood Spot 12.3 Neonatal Hypoglycemia, Thermoregulation & the Infant of a Diabetic Mother 12.4 Neonatal Hyperbilirubinemia & Phototherapy 12.5 Infant Feeding Education, Circumcision Counseling & Care Through 28 Days
13 Chapter 13: Well-Woman Preventive Care, Cancer Screening & Immunization
13.1 The Well-Woman Visit & Cervical Cancer Screening 13.2 ASCCP Risk-Based Management & Breast Cancer Screening 13.3 Colorectal Cancer & Osteoporosis Screening 13.4 Adult Immunization & Environmental and Occupational Exposure Screening
14 Chapter 14: Contraception, Abortion Care & Fertility Evaluation
14.1 Contraceptive Efficacy Tiers & Long-Acting Reversible Contraception 14.2 Combined Hormonal Contraception 14.3 Progestin-Only Methods & Emergency Contraception 14.4 Abortion Care: Options Counseling, Medication Abortion & Follow-Up 14.5 Initial Infertility Evaluation & Gynecologic Imaging Referral
15 Chapter 15: Benign Gynecologic Conditions, Pelvic Floor & Menstrual Disorders
15.1 Endometriosis & Adenomyosis 15.2 Pelvic Organ Prolapse & Urinary Incontinence 15.3 Adnexal Masses, Malignancy Red Flags & Vulvar Disease 15.4 The Normal Menstrual Cycle & Anticipatory Guidance 15.5 The FIGO PALM-COEIN Classification of Abnormal Uterine Bleeding 15.6 Evaluating Abnormal Uterine Bleeding & the Amenorrhea Workup 15.7 Polycystic Ovary Syndrome
16 Chapter 16: Vaginitis, Sexually Transmitted Infections, Sexual Health & Menopause
16.1 Differential Diagnosis of Vaginitis & Bacterial Vaginosis 16.2 Candidiasis, Trichomoniasis, Chlamydia & Gonorrhea 16.3 Pelvic Inflammatory Disease 16.4 Genital Herpes, Syphilis & Anogenital Warts 16.5 Sexual Health Assessment, Sexual Function & Care After Sexual Assault 16.6 Reproductive Aging, Menopause Definitions & Clinical Manifestations 16.7 Menopausal Hormone Therapy 16.8 Non-Hormonal Therapies & Postmenopausal Osteoporosis
17 Chapter 17: Primary Care — Chronic Disease & Common Acute Conditions
17.1 Midwifery Primary Care Scope & Hypertension Management 17.2 Antihypertensive Pharmacotherapy & Hyperlipidemia 17.3 Type 2 Diabetes & Thyroid Disease in Primary Care 17.4 Respiratory Infections, Asthma & Urinary Tract Infection 17.5 Gastrointestinal & Dermatologic Conditions 17.6 Mental Health Screening & Substance Use Disorders 17.7 Intimate Partner Violence, Reproductive Coercion & Human Trafficking
18 Chapter 18: Midwifery Scope of Practice, Ethics, Collaboration & Health Equity
18.1 Regulatory Foundation of Practice & the Midwifery Model of Care 18.2 Bioethics, Informed Refusal & Collaborative Practice 18.3 Maternal Health Disparities, Structural Racism & Inclusive Care
3.2 Acute Severe Hypertension, Magnesium Sulfate & Eclampsia
Key Takeaways Explain This Topic AI
Severe-range hypertension is systolic 160 mmHg or higher or diastolic 110 mmHg or higher sustained 15 minutes or longer, and must be treated within 30 to 60 minutes to prevent maternal stroke.
Magnesium sulfate is loaded at 4 to 6 g intravenously over 20 to 30 minutes and maintained at 1 to 2 g per hour, monitored by patellar reflexes, respiratory rate of 12 or more per minute, and urine output of 30 mL per hour or more.
Loss of deep tendon reflexes is the earliest clinical sign of magnesium toxicity, and the antidote is calcium gluconate 1 g intravenously over 3 to 5 minutes after stopping the infusion.
Immediate-release nifedipine must be swallowed whole, never chewed or given sublingually, because erratic absorption can cause dangerous maternal hypoperfusion.
Prolonged fetal bradycardia during and after an eclamptic seizure typically resolves within 3 to 10 minutes of maternal stabilization, so the mother is resuscitated before any decision about emergent delivery.
Last updated: September 2026
Acute Management of Severe-Range Hypertension
A hypertensive emergency in pregnancy is defined as acute-onset, severe-range blood pressure ( systolic BP ≥160 mmHg and/or diastolic BP ≥110 mmHg ) that is sustained for 15 minutes or longer . Severe-range blood pressure is an obstetric emergency that drastically elevates maternal risk for hemorrhagic stroke, hypertensive encephalopathy, cardiopulmonary decompensation, and placental abruption.
Treatment Goals and Clinical Timing
Goal: Lower systolic BP to 140–150 mmHg and diastolic BP to 90–100 mmHg within 30 to 60 minutes of confirmation.
Precaution: Avoid precipitous drops in blood pressure (e.g., diastolic BP <80 mmHg), which can cause maternal cerebral hypoperfusion and impair uteroplacental blood flow, resulting in non-reassuring fetal heart rate tracings.
- First-Line Pharmacologic Algorithms [ Severe-Range BP Detected: SBP ≥160 or DBP ≥110 mmHg ]
- │
- Confirm persistence within 15 minutes
- │
- ┌──────────────────────────────┼──────────────────────────────┐
- ▼ ▼ ▼
- [ IV Labetalol ] [ IV Hydralazine ] [ Oral IR Nifedipine ]
- 20 mg IV over 2 min 5–10 mg IV over 2 min 10–20 mg PO (swallow)
- │ │ │
- Recheck BP at 10 min Recheck BP at 20 min Recheck BP at 20 min
- │ │ │
If still severe: If still severe: If still severe:
- 40 mg IV over 2 min 10 mg IV over 2 min 20 mg PO
- │ │ │
- Recheck BP at 10 min Recheck BP at 20 min Recheck BP at 20 min
- │ │ │
If still severe: If still severe: If still severe:
- 80 mg IV over 2 min Switch to Labetalol 20 mg PO (max 50 mg)
- (Max single dose 80 mg; or Nifedipine (Switch to IV line)
- cumulative max 220–300 mg) (Max dose 20–30 mg)
- 1. Intravenous Labetalol
Mechanism: Combined non-selective beta-blocker and selective alpha-1 adrenergic blocker, decreasing systemic vascular resistance without significant reflex tachycardia.
Dosing Protocol: Initial bolus of 20 mg IV over 2 minutes. If severe hypertension persists after 10 minutes, administer 40 mg IV . If still severe at 10 minutes, administer 80 mg IV . If still severe at 10 minutes, administer another 80 mg IV (maximum cumulative initial bolus dose: 220–300 mg). If control is not achieved, switch to hydralazine or nifedipine.
Contraindications: Avoid in patients with asthma, severe reactive airway disease, decompensated heart failure, or severe sinus bradycardia (<60 bpm).
2. Intravenous Hydralazine
Mechanism: Direct arteriolar smooth muscle vasodilator.
Dosing Protocol: Initial bolus of 5 to 10 mg IV over 2 minutes. Recheck blood pressure in 20 minutes. If severe hypertension persists, administer 10 mg IV . If still severe after another 20 minutes, switch class (cumulative maximum dose: 20–30 mg).
Midwifery Considerations: Hydralazine has a slower onset (10–20 minutes) and longer duration of action; rapid redosing can lead to profound maternal hypotension, reflex tachycardia, maternal headache, and fetal decelerations.
3. Oral Immediate-Release Nifedipine
Mechanism: Dihydropyridine calcium channel blocker inhibiting transmembrane calcium influx in vascular smooth muscle.
Dosing Protocol: 10 to 20 mg PO swallowed whole with water (never puncture, chew, or administer sublingually, which can cause erratic absorption and dangerous hypoperfusion). If severe hypertension persists at 20 minutes, administer 20 mg PO . If still severe at 40 minutes, administer another 20 mg PO (maximum cumulative initial dose: 50 mg).
Clinical Advantage: Outstanding first-line choice when intravenous access has not yet been secured or in outpatient triage settings.
Seizure Prophylaxis: Magnesium Sulfate
Intravenous magnesium sulfate is the uncontested gold-standard pharmacologic agent for the prevention and treatment of eclamptic seizures. It is significantly superior to phenytoin, diazepam, and nimodipine. Magnesium acts centrally by blocking N-methyl-D-aspartate (NMDA) receptors, raising seizure thresholds, and producing cerebral vasodilation that alleviates preeclamptic cerebral vasospasm.
Clinical Indications
All patients with preeclampsia with severe features , eclampsia , or HELLP syndrome during labor and for at least 24 hours postpartum.
In patients with preeclampsia without severe features, routine administration is debated; shared decision-making and individualized assessment of clinical risk factors guide utilization.
Administration Protocols
Loading Dose: 4 to 6 grams IV diluted in 100 mL of 5% Dextrose or 0.9% Normal Saline administered via an infusion pump over 20 to 30 minutes .
Maintenance Infusion: 1 to 2 grams/hour continuous intravenous infusion.
Intramuscular Alternative (Pritchard Regimen): Utilized when IV access is impossible or during transport: 4 g IV load plus 10 g IM (5 g in each buttock of 50% solution deep IM with 1% lidocaine), followed by 5 g IM every 4 hours into alternating buttocks.
Mandatory Clinical Monitoring & Toxicity Manifestations
Because magnesium is eliminated almost exclusively by the kidneys, maternal renal insufficiency can cause rapid accumulation and life-threatening toxicity. Serum Magnesium Level (mg/dL) Clinical Findings / Toxicity Stage
- ─────────────────────────────────────────────────────────────────────────
- 4.8 – 8.4 mg/dL (4–7 mEq/L) Therapeutic Target Range
- 9.0 – 12.0 mg/dL (7–10 mEq/L) Loss of Deep Tendon (Patellar) Reflexes
- 12.0 – 15.0 mg/dL (10–12 mEq/L) Respiratory Depression (<12 breaths/min)
- 15.0 – 17.0 mg/dL (12–15 mEq/L) Altered Mental Status, Somnolence, Slurred Speech
- >20.0 mg/dL (>15 mEq/L) Cardiac Arrest, Asystole, Complete Heart Block
Serial Bedside Checks (Hourly):
Patellar Reflexes: Must be present (+1 to +2). Loss of reflexes is the earliest clinical herald of impending toxicity.
Respiratory Rate: Must be ≥12 breaths/minute . Count for a full 60 seconds.
Urine Output: Must be ≥30 mL/hour (or ≥100 mL every 4 hours). If urine output drops below 30 mL/hr, serum magnesium levels will rise rapidly; reduce maintenance rate, obtain stat serum level, and monitor closely.
Continuous Pulse Oximetry: Maintain SpO2 ≥95%.
Reversal of Magnesium Toxicity
If clinical signs of magnesium toxicity develop (loss of DTRs with bradypnea, severe somnolence, or cardiac compromise):
Immediately discontinue the magnesium sulfate infusion.
Call for emergency assistance and administer supplemental oxygen (10 L/min via non-rebreather mask).
Administer the direct antagonist: Calcium gluconate 1 gram IV (10 mL of a 10% solution) infused slowly over 3 to 5 minutes .
Support airway, breathing, and circulation; prepare for endotracheal intubation if respiratory arrest ensues.
Managing an Eclamptic Seizure at the Bedside
Eclampsia is a new-onset generalized tonic-clonic seizure in a patient with preeclampsia that is not attributable to another cause. It is the emergency that magnesium prophylaxis exists to prevent, and the midwife must be able to run the response.
Timing. Roughly one third of eclamptic seizures occur postpartum , most within the first 48 hours, and late postpartum eclampsia can occur up to 4 weeks after birth . Up to 20–38% of eclamptic seizures occur with no preceding classic warning signs, so the absence of headache or visual change never excludes the diagnosis.
Immediate Sequence
Call for help and activate the obstetric emergency response; note the time the seizure began.
Protect the patient, do not restrain her. Lower the bed, pad side rails, remove hard objects. Never force an airway, bite block, or tongue depressor into the mouth.
Position left lateral to reduce aspiration risk and relieve aortocaval compression.
Airway and oxygen: suction oral secretions after the tonic-clonic activity stops; apply oxygen 8–10 L/min by non-rebreather mask . Most seizures are self-limited at 60–90 seconds .
Magnesium sulfate is both the treatment and the ongoing prophylaxis: 4–6 g IV load over 15–20 minutes , then 2 g/hour . If a seizure recurs while on magnesium, give an additional 2 g IV bolus over 3–5 minutes .
Refractory seizures (a third seizure, or status) require a benzodiazepine (lorazepam 2–4 mg IV) or levetiracetam, anesthesia support for possible intubation, and neuroimaging to exclude intracranial hemorrhage or posterior reversible encephalopathy syndrome (PRES).
Control severe-range blood pressure with IV labetalol, IV hydralazine, or oral immediate-release nifedipine once the seizure has ended.
Caution
Do not rush to cesarean during or immediately after the seizure. Maternal hypoxia and hypercarbia during the convulsion routinely produce prolonged fetal bradycardia, late decelerations, and reduced variability that resolve over 3 to 10 minutes once the mother is oxygenated and stabilized. Stabilize the mother first — maternal resuscitation is fetal resuscitation. Operating on an unstable, seizing patient increases maternal risk without improving neonatal outcome.
After Stabilization
Reassess maternal vital signs, neurologic status, and reflexes; draw a full preeclampsia panel including CBC, LDH, transaminases, creatinine, and coagulation studies.
Delivery is indicated after maternal stabilization at any gestational age. Vaginal birth is preferred when the cervix is favorable and the fetal status allows.
Continue magnesium sulfate for at least 24 hours after the last seizure or after birth , whichever is later.
Investigate alternative causes if the seizure is atypical, focal, or occurs without hypertension: intracranial hemorrhage, cerebral venous thrombosis, hypoglycemia, hyponatremia, epilepsy, or drug toxicity.